Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the Role of APC in Modulating Chemotherapeutic Response in Triple-Negative Breast Cancer cells.

bioRxiv : the preprint server for biology·2026
Same author

Editorial: Clinical implementation of precision oncology data to direct individualized and immunotherapy-based treatment strategies.

Frontiers in immunology·2025
Same author

Bcl-2 Up-Regulation Mediates Taxane Resistance Downstream of APC Loss.

International journal of molecular sciences·2024
Same author

APC Loss Prevents Doxorubicin-Induced Cell Death by Increasing Drug Efflux and a Chemoresistant Cell Population in Breast Cancer.

International journal of molecular sciences·2023
Same author

Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential.

International journal of molecular sciences·2023
Same author

Chicago EYES on Cancer: Fostering Diversity in Biomedicine through Cancer Research Training for Students and Teachers.

Journal of STEM outreach·2022
Same journal

Extracellular Vesicles from Mesenchymal Stem Cells Alleviate Spinal Cord Injury via the miR-486-5p/PTEN/PI3K/AKT Pathway.

Current drug targets·2026
Same journal

Improving B-cell Linear Epitope Prediction <i>via</i> Multiple Feature Fusion and an Integrated Machine Learning Algorithm.

Current drug targets·2026
Same journal

Mechanistic Insights into the Inhibition of Plasmodium falciparum DNA Gyrase A by Withanolide Derivatives through Integrated Computational Analysis.

Current drug targets·2026
Same journal

Epitranscriptomics in Breast Cancer: The Unveiled Role of RNA Modifications.

Current drug targets·2026
Same journal

Neuroinflammation in Alzheimer's Disease: New Approaches.

Current drug targets·2026
Same journal

FXYD3: A Key Regulator of Ion Homeostasis and Redox Balance in Cancer Biology.

Current drug targets·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Artificial Antigen Presenting Cell aAPC Mediated Activation and Expansion of Natural Killer T Cells
13:18

Artificial Antigen Presenting Cell aAPC Mediated Activation and Expansion of Natural Killer T Cells

Published on: December 29, 2012

18.2K

Exploiting APC function as a novel cancer therapy.

Alyssa C Lesko, Kathleen H Goss, Jenifer R Prosperi1

  • 1Department of Biochemistry and Molecular Biology, Indiana University School of Medicine - South Bend, 1234 Notre Dame Ave, South Bend, IN 46617, USA. jrprospe@iupui.edu.

Current Drug Targets
|November 9, 2013
PubMed
Summary
This summary is machine-generated.

The Adenomatous Polyposis Coli (APC) tumor suppressor is crucial in preventing epithelial cancers. Loss of APC function contributes to tumor progression and therapeutic resistance, highlighting its potential as a therapeutic target.

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.5K
Killer Artificial Antigen Presenting Cells KaAPC for Efficient In Vitro Depletion of Human Antigen-specific T Cells
08:12

Killer Artificial Antigen Presenting Cells KaAPC for Efficient In Vitro Depletion of Human Antigen-specific T Cells

Published on: August 11, 2014

9.5K

Related Experiment Videos

Last Updated: May 6, 2026

Artificial Antigen Presenting Cell aAPC Mediated Activation and Expansion of Natural Killer T Cells
13:18

Artificial Antigen Presenting Cell aAPC Mediated Activation and Expansion of Natural Killer T Cells

Published on: December 29, 2012

18.2K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.5K
Killer Artificial Antigen Presenting Cells KaAPC for Efficient In Vitro Depletion of Human Antigen-specific T Cells
08:12

Killer Artificial Antigen Presenting Cells KaAPC for Efficient In Vitro Depletion of Human Antigen-specific T Cells

Published on: August 11, 2014

9.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The Adenomatous Polyposis Coli (APC) tumor suppressor is frequently mutated in various epithelial cancers, including colorectal, breast, pancreatic, and lung cancers.
  • APC mutations lead to a truncated protein, loss of function, and are implicated in early cancer development, marking APC as a critical gatekeeper.
  • APC regulates numerous cellular functions beyond Wnt/β-catenin signaling, including polarity, microtubule dynamics, cell cycle, DNA repair, apoptosis, and migration.

Purpose of the Study:

  • To review the normal functions of APC and their implications for cancer treatment.
  • To discuss the role of APC loss in epithelial tumorigenesis.
  • To provide an overview of therapeutic strategies targeting both Wnt-dependent and Wnt-independent functions of APC.

Main Methods:

  • Literature review of studies on APC function, mutations, and therapeutic strategies.
  • Analysis of APC's role in various epithelial cancers.
  • Synthesis of current and emerging therapeutic approaches targeting APC.

Main Results:

  • Loss of APC function contributes to cancer development and chemoresistance by disrupting normal cellular processes.
  • APC's multifaceted roles offer multiple avenues for therapeutic intervention.
  • Therapeutic strategies include APC reintroduction, targeting activated pathways, and inducing apoptosis in APC-mutant cells.

Conclusions:

  • APC is a vital tumor suppressor with diverse cellular functions, making its loss a significant driver of cancer.
  • Targeting APC's Wnt-dependent and -independent functions presents promising therapeutic opportunities for epithelial cancers.
  • Restoring or compensating for APC loss is a key strategy for overcoming therapeutic resistance in APC-mutant cancers.